- Details
- Based on the SPARTAN and TITAN studies, apalutamide is approved for patients with nonmetastatic castration-resistant and metastatic castration-sensitive prostate cancer. Skin rash was a common adverse reaction across indications. We hypothesized that earlier identification and intervention could improve rash outcomes. Biographies: Jason Hafron, MD, CMO, Oncologist, Director of Research, Michigan I...
|
- Details
- Andrea Miyahira interviews Abhijit Parolia about his group's study on NSD2's role in prostate cancer. Dr. Parolia explains how NSD2, a histone methyltransferase, reprograms androgen receptor (AR) activity in prostate cancer cells. The research reveals that NSD2 is upregulated in malignant prostate tissue and is crucial for AR binding to chimeric AR-FOXA1 sites, promoting tumor growth. Using CRISPR...
|
- Details
- Defining optimal therapeutic sequencing strategies in prostate cancer (PC) is challenging and may be assisted by artificial intelligence (AI)-based tools for an analysis of the medical literature. To demonstrate that INSIDE PC can help clinicians query the literature on therapeutic sequencing in PC and to develop previously unestablished practices for evaluating the outputs of AI-based support pla...
|
- Details
- Rashid Sayyid converses with Dr. Neil Fleshner about the outcomes of the MAST trial, which examined the effects of metformin on patients under active surveillance for prostate cancer. Despite promising preclinical evidence suggesting metformin's potential benefits against prostate cancer, the trial results were unexpectedly negative, showing no significant advantage of metformin in preventing canc...
|
- Details
- Bruce Montgomery discusses the pivotal role of germline testing in cancer predisposition, particularly within the Million Veterans Program. Focusing on prostate cancer, Dr. Montgomery explains that germline testing, which examines inherited DNA, can identify individuals with genetic predispositions to various cancers, including prostate, breast, ovarian, and pancreatic. This testing is crucial for...
|
- Details
- Andrea Miyahira talks with Hiba Khan about her presentation on germline genetic associations in prostate cancer. Dr. Khan's study, leveraging data from Invitae, explores genetic testing results linked to medical records to identify gene-specific associations and potential disparities in testing among diverse populations. Key findings reveal that BRCA2 is the most common mutation across all demogra...
|
- Details
- Matthew Cooperberg, alongside patient advocates Stan Rosenfeld, Bruce Zweig, Nathan Roundy, and Leszek Izdebski, engages in a comprehensive Q&A session with Neal Shore, Stephen Freedland, and Rana McKay. They explore the potential applications of enzalutamide for low-risk prostate cancer patients on active surveillance, referencing findings from the ENACT and EMBARK trials. Dr. Shore emphasizes th...
|
- Details
- Matthew Cooperberg is joined by Steve Freedland, Neal Shore, and Rana McKay to discuss the findings from the EMBARK trial, a landmark study examining treatments for prostate cancer patients experiencing biochemical recurrence. The EMBARK trial compares traditional androgen deprivation therapy (ADT) using leuprolide alone, with the addition of enzalutamide, and enzalutamide alone. Drs. Freedland an...
|
- Details
- Ping Mu discusses his team's paper, "ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity in AR-Targeted Therapy Resistance in Prostate Cancer," published in Cancer Discovery. Dr. Mu explains that while primary prostate cancer can be managed effectively, resistance to androgen receptor (AR)-targeted therapies in metastatic cases remains a significant challenge. His research identifies the zin...
|
- Details
- Andrea Miyahira interviews Estefania Labanca about her team's work, featured in the paper "Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-Derived Xenograft Series." Dr. Labanca highlights the MD Anderson Prostate Cancer Patient-Derived Xenograft (MDA PCa PDX) Program, a pioneering effort started over 30 years ago by Dr. Navone to model lethal prostate cancer, especially...
|
